Trevi Therapeutics, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing Haduvio, oral nalbuphine ER, for chronic cough indications including IPF-related chronic cough, non-IPF interstitial lung disease, and refractory chronic cough. Its 8-K filings report financial results, clinical development updates, FDA meeting disclosures, and material events related to the Haduvio program.
The company’s SEC record also includes registration and offering materials for common stock financings, underwriting agreements, and proxy disclosures covering director elections, executive compensation, governance matters, and equity-based compensation. These filings describe Trevi’s capital structure, development-stage operating profile, and public-company governance.
Trevi Therapeutics (TRVI) filed a Form 144 reporting a proposed sale of common stock through Stifel Nicolaus & Company. The notice lists 312,855 shares to be sold with an aggregate market value of $2,532,530, against total shares outstanding of 121,776,855. The approximate date of sale is 08/27/2025 and the securities exchange is Nasdaq.
The filing discloses how the shares were acquired: 65,712 shares from restricted stock units dated 02/15/2023 (paid 02/16/2023 in cash) and 259,576 shares from an option exercise dated 02/26/2023 (paid 02/16/2023 in cash). No securities were reported sold by the person in the past three months. The filer signs the standard representation that they do not possess nonpublic material adverse information about the issuer.
Trevi Therapeutics reports that Chief Financial Officer Lisa Delfini will end her employment and resign as CFO on August 22, 2025. The company states that her resignation is not due to any disagreement over operations, policies, or practices. In line with its Executive Separation Benefits and Retention Plan, Trevi has agreed to provide her with separation benefits, conditioned on signing a severance and release agreement that includes a general release of claims, a non-disparagement commitment, and reaffirmation of existing confidentiality, non-solicitation, and non-compete obligations.
As of the effective date of her departure, President and Chief Executive Officer Jennifer L. Good will also serve as the company’s principal financial officer on an interim basis until a new principal financial officer is designated.
Viking Global Investors and affiliated entities report beneficial ownership of 7,505,694 shares of Trevi Therapeutics (TRVI), representing 5.9% of the common stock. The holdings consist of 1,543,000 shares directly owned by two affiliated entities (1,033,810 by VGOP and 509,190 by VGOD) and 5,962,694 shares issuable upon exercise of pre-funded warrants exercisable at $0.001 per share. The filing clarifies the ownership chain through multiple Delaware and Cayman entities and notes shared voting and dispositive power among the reporting persons, including O. Andreas Halvorsen, David C. Ott and Rose S. Shabet. The statement affirms these securities were not acquired to change or influence control of the issuer.
NEA amendments report current holdings and a dilution-driven decrease in stake. The filing discloses that New Enterprise Associates and affiliated reporting persons collectively beneficially own 15,074,080 shares of Trevi Therapeutics common stock, representing 12.0% of the outstanding class on the basis stated in the filing. NEA 16 is shown as the record owner of 10,421,428 shares and as holding warrants exercisable for 3,703,704 shares; NEA 18 VGE holds 948,948 shares. The ownership figures reflect shared voting and dispositive power among the reporting entities and individuals.
The amendment explains the decrease in the percentage ownership as resulting from an increase in the number of shares outstanding, and reiterates that the Funds acquired the shares for investment purposes. The filing states there are no present plans by the reporting persons to pursue corporate actions such as board changes, asset sales, or extraordinary transactions, and notes that no transactions were effected by the reporting persons in the last 60 days. Exhibits include the joint filing agreement and a power of attorney.